A phase 2 randomized, double-blind, placebo-controlled trial of radium-223 dichloride with exemestane and everolimus in patients with HER2-negative hormone receptor-positive breast cancer and bone metastases

被引：0
|
作者：
Rugo, H. [1 ]
Petrenciuc, O. [2 ]
Zhang, A. [3 ]
Li, R. [4 ]
Coleman, R. E. [5 ]
机构：
[1] UCSF Helen Diller Family Comprehens Canc Ctr, Med, San Francisco, CA USA
[2] Pharmaceut Div Bayer, Global Clin Dev, Whippany, NJ USA
[3] Pharmaceut Div Bayer, Global Dev, Whippany, NJ USA
[4] Pharmaceut Div Bayer, Global Res & Dev Stat, Whippany, NJ USA
[5] Univ Sheffield, Weston Pk Hosp, Oncol, Sheffield, S Yorkshire, England
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
10.1093/annonc/mdw365.89
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
310TiP
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Molecular classification of hormone receptor-positive HER2-negative breast cancer
    Jin, Xi
    Zhou, Yi-Fan
    Ma, Ding
    Zhao, Shen
    Lin, Cai-Jin
    Xiao, Yi
    Fu, Tong
    Liu, Cheng-Lin
    Chen, Yi-Yu
    Xiao, Wen-Xuan
    Liu, Ya-Qing
    Chen, Qing-Wang
    Yu, Ying
    Shi, Le-Ming
    Shi, Jin-Xiu
    Huang, Wei
    Robertson, John F. R.
    Jiang, Yi-Zhou
    Shao, Zhi-Ming
    NATURE GENETICS, 2023, 55 (10) : 1696 - +
  • [42] Challenges in the treatment of hormone receptor-positive, HER2-negative metastatic breast cancer with brain metastases
    Minetta C. Liu
    Javier Cortés
    Joyce O’Shaughnessy
    Cancer and Metastasis Reviews, 2016, 35 : 323 - 332
  • [43] Efficacy and safety of the combination of metformin, everolimus and exemestane in overweight and obese postmenopausal patients with metastatic, hormone receptor-positive, HER2-negative breast cancer: a phase II study
    Yam, Clinton
    Esteva, Francisco J.
    Patel, Miral M.
    Raghavendra, Akshara S.
    Ueno, Naoto T.
    Moulder, Stacy L.
    Hess, Kenneth R.
    Shroff, Girish S.
    Hodge, Silvia
    Koenig, Kimberly H.
    Mac Gregor, Mariana Chavez
    Griner, Robin L.
    Yeung, Sai-Ching J.
    Hortobagyi, Gabriel N.
    Valero, Vicente
    INVESTIGATIONAL NEW DRUGS, 2019, 37 (02) : 345 - 351
  • [44] Management of hormone receptor-positive, HER2-negative early breast cancer
    Walsh, Elaine M.
    Smith, Karen L.
    Stearns, Vered
    SEMINARS IN ONCOLOGY, 2020, 47 (04) : 187 - 200
  • [45] Molecular classification of hormone receptor-positive HER2-negative breast cancer
    Xi Jin
    Yi-Fan Zhou
    Ding Ma
    Shen Zhao
    Cai-Jin Lin
    Yi Xiao
    Tong Fu
    Cheng-Lin Liu
    Yi-Yu Chen
    Wen-Xuan Xiao
    Ya-Qing Liu
    Qing-Wang Chen
    Ying Yu
    Le-Ming Shi
    Jin-Xiu Shi
    Wei Huang
    John F. R. Robertson
    Yi-Zhou Jiang
    Zhi-Ming Shao
    Nature Genetics, 2023, 55 : 1696 - 1708
  • [46] Challenges in the treatment of hormone receptor-positive, HER2-negative metastatic breast cancer with brain metastases
    Liu, Minetta C.
    Cortes, Javier
    O'Shaughnessy, Joyce
    CANCER AND METASTASIS REVIEWS, 2016, 35 (02) : 323 - 332
  • [47] Efficacy and safety of the combination of metformin, everolimus and exemestane in overweight and obese postmenopausal patients with metastatic, hormone receptor-positive, HER2-negative breast cancer: a phase II study
    Clinton Yam
    Francisco J. Esteva
    Miral M. Patel
    Akshara S. Raghavendra
    Naoto T. Ueno
    Stacy L. Moulder
    Kenneth R. Hess
    Girish S. Shroff
    Silvia Hodge
    Kimberly H. Koenig
    Mariana Chavez Mac Gregor
    Robin L. Griner
    Sai-Ching J. Yeung
    Gabriel N. Hortobagyi
    Vicente Valero
    Investigational New Drugs, 2019, 37 : 345 - 351
  • [48] Efficacy of palbociclib after everolimus in hormone receptor-positive, HER2-negative advanced breast cancer.
    Kovac, Anja
    Kuhar, Cvetka Grasic
    Ovcaricek, Tanja
    Matos, Erika
    Mencinger, Marina
    Borstnar, Simona
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [49] Re: Addition of Radium-223 to Abiraterone Acetate and Prednisone or Prednisolone in Patients with Castration-resistant Prostate Cancer and Bone Metastases (ERA 223): A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial
    van der Poel, Henk
    EUROPEAN UROLOGY, 2019, 76 (05) : 705 - 706
  • [50] Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial (vol 18, pg 904, 2017)
    Baselga, J.
    Im, S-A
    Iwata, H.
    LANCET ONCOLOGY, 2019, 20 (02): : E71 - E72
12345